Chris Painter’s research focuses on using health economics and health technology assessment methods to inform resource allocation policy decisions for a wide range of communicable and non-communicable diseases. This typically involves a comparison between the economic costs and health impacts of different health interventions to understand which intervention(s) are most cost-effective to use in practice.
A Health Economist at MORU MAEMOD’s Neglected Tropical Diseases Modeling (NTDM) Group since 2022, Chris’ current work focusses on: (ACORN) A Clinically Oriented antimicrobial Resistance Network; the ACT-South Asia (Azithromycin and Cefixime treatment of typhoid in South Asia) trial; and working with LOMWRU, MORU’s Lao PDR Unit, on the newly formed Unit for Health Evidence and Policy (UHEP) in Vientiane.
Chris’ ongoing research interests include antimicrobial resistance (AMR); COVID-19; Hepatitis C virus; and health economics and health technology assessment methods and institutionalising these methods in low- and middle-income countries (LMICs)
Holder of both an MSc and a BSc Economics from the University of Manchester, prior to MORU Chris worked as a health economist in the UK private sector and as an Overseas Development Institute Fellow (2019-2022) at the Health Intervention and Technology Assessment Program (HITAP) in Thailand’s Ministry of Public Health.
Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic.
Wang Y. et al, (2022), The European journal of health economics : HEPAC : health economics in prevention and care
A model-based study to estimate the health and economic impact of health technology assessment in Thailand.
Kingkaew P. et al, (2022), International journal of technology assessment in health care, 38
A protocol for a systematic literature review of economic evaluation studies of interventions to address antimicrobial resistance.
Ananthakrishnan A. et al, (2021), Systematic reviews, 10
Avoiding health technology assessment: a global survey of reasons for not using health technology assessment in decision making.
Teerawattananon Y. et al, (2021), Cost effectiveness and resource allocation : C/E, 19
Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines.
Painter C. et al, (2021), Applied health economics and health policy, 19, 463 - 472